nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

16.08.2016 | Original Article – Cancer Research

Endothelin-1 (ET-1) induces resistance to bortezomib in human multiple myeloma cells via a pathway involving the ETB receptor and upregulation of proteasomal activity

verfasst von: Maria Vaiou, Evanthia Pangou, Panagiotis Liakos, Nikos Sakellaridis, George Vassilopoulos, Konstantinos Dimas, Christos Papandreou

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 10/2016

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Bortezomib (BTZ) is used for the treatment of multiple myeloma (MM). However, a significant proportion of patients may be refractory to the drug. This study aimed to investigate whether the endothelin (ET-1) axis may act as an escape mechanism to treatment with bortezomib in MM cells.

Methods

NCI-H929 and RPMI-8226 (human MM cell lines) were cultured with or without ET-1, BTZ, and inhibitors of the endothelin receptors. ET-1 levels were determined by ELISA, while the protein levels of its receptors and of the PI3K and MAPK pathways’ components by western blot. Effects of ET-1 on cell proliferation were studied by MTT and on the ubiquitin proteasome pathway by assessing the chymotryptic activity of the 20S proteasome in cell lysates.

Results

Endothelin receptors A and B (ET_AR and ET_BR, respectively) were found to be expressed in both cell lines, with the RPMI-8226 cells that are considered resistant to BTZ, expressing higher levels of ET_BR and in addition secreting ET-1. Treatment of the NCI-H929 cells with ET-1 increased proliferation, while co-incubation of these cells with ET-1 and BTZ decreased BTZ efficacy with concomitant upregulation of 20S proteasomal activity. Si-RNA silencing or chemical blockade of ET_BR abrogated the protective effects of ET-1. Finally, data suggest that the predominant signaling pathway involved in ET-1/ET_BR-induced BTZ resistance in MM cells may be the MAPK pathway.

Conclusion

Our data suggest a possible role of the ET-1/ET_BR axis in regulating the sensitivity of MM cells to BTZ. Thus, combining bortezomib with strategies to target the ET-1 axis could prove to be a novel promising therapeutic approach in MM.

Nur mit Berechtigung zugänglich

Adachi M, Yang YY, Furuichi Y, Miyamoto C (1991) Cloning and characterization of cDNA encoding human A-type endothelin receptor. Biochem Biophys Res Commun 180:1265–1272PubMedCrossRef

Adams J (2003) The proteasome: structure, function and role in the cell. Cancer Treat Rev 29:3–9PubMedCrossRef

Ali H, Loizidou M, Dashwood M, Savage F, Sheard C, Taylor I (2000) Stimulation of colorectal cancer cell line growth by ET-1 and its inhibition by ET(A) antagonists. Gut 47:685–688PubMedPubMedCentralCrossRef

Anguelova E, Beuvon F, Leonard N, Chaverot N, Varlet P, Couraud PO et al (2005) Functional endothelin ETB receptors are selectively expressed in human oligodendrogliomas. Brain Res Mol Brain Res 137:77–88PubMedCrossRef

Bagnato A (2012) The endothelin axis as therapeutic target in human malignancies: present and future. Curr Pharm Des 18:2720–2733PubMedCrossRef

Bagnato A, Natali PG (2004a) Endothelin receptors as novel targets in tumor therapy. J Transl Med 2:16PubMedPubMedCentralCrossRef

Bagnato A, Natali PG (2004b) Targeting endothelin axis in cancer. Cancer Treat Res 119:293–314PubMedCrossRef

Bagnato A, Rosano LE (2008) The endothelin axis in cancer. Int J Biochem Cell Biol 40:1443–1451PubMedCrossRef

Bagnato A, Tecce R, Moretti C et al (1995) Autocrine actions of endothelin-1 as a growth factor in human ovarian carcinoma cells. Clin Cancer Res 1:1059–1066PubMed

Bagnato A, Tecce R, Di Castro V, Catt KJ (1997) Activation of mitogenic signaling by endothelin-1 in ovarian carcinoma cells. Cancer Res 57:1306–1311PubMed

Bagnato A, Salani D, Di Castro V, Wu-Wong JR, Tecce R, Nicotra A, Venuti A, Natali PG (1999) Expression of endothelin-1 and endothelin A receptor in ovarian carcinoma: evidence for an autocrine role in tumor growth. Cancer Res 59:720–727PubMed

Bagnato A, Rosano L, Spinella F, Di Castro V, Tecce R et al (2004) Endothelin B receptor blockade inhibits dynamics of cell interactions and communications in melanoma cell progression. Cancer Res 64:1436–1443PubMedCrossRef

Bagnato A, Loizidou M, Pflug BR, Curwen J, Growcott J (2011) Role of the endothelin axis and its antagonists in the treatment of cancer. Br J Pharmacol 163:220–233PubMedPubMedCentralCrossRef

Balsas P, Lopez-Royuela N, Galan-Malo P, Anel A, Marzo I, Naval J (2009) Cooperation between Apo2L/TRAIL and bortezomib in multiple myeloma apoptosis. Biochem Pharmacol 77:804–812PubMedCrossRef

Bednar DL, Stein RB, Garsky VM, Williams DL (1991) The bovine endothelin receptor has an apparent molecular weight of 43,000. Biochem Biophys Acta 1092:226–232PubMedCrossRef

Berger Y, Bernasconni CC, Juillerat-Jeanneret L (2006) Targeting the endothelin axis in human melanoma: combination of endothelin receptor antagonism and alkylating agents. Exp Biol Med 231:1111–1119

Bergsagel PL, Kuehl WM (2005) Molecular pathogenesis and a consequent classification of multiple myeloma. J Clin Oncol 23:6333–6338PubMedCrossRef

Bianchi G, Oliva L, Cascio P, Pengo N, Fontana F et al (2009) The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition. Blood 113:3040–3049PubMedCrossRef

Bittner M, Meltzer P, Chen Y, Jiang Y, Seftor E et al (2000) Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature 406:536–540PubMedCrossRef

Codony-Servat J, Tapia MA, Bosch M et al (2006) Differential and molecular effects of bortezomib, a proteasome inhibitor, in human breast cancer cells. Mol Cancer Ther 5:665–675PubMedCrossRef

Conner TM, Doan QD, Walters IB, LeBlanc AL, Beveridge RA (2008) An observational retrospective analysis of retreatment with bortezomib for multiple myeloma. Clin Lymphoma Myeloma 8:140–145PubMedCrossRef

Cyr C, Huebner K, Druck T, Kris R (1991) Cloning and chromosomal localization of a human endothelin ETA receptor. Biochem Biophys Res Commun 181:184–190PubMedCrossRef

De Giorgio L, Tazzari PL, Barbara G et al (1998) Detection of substance P immunoreactivity in human peripheral leukocytes. J Neuroimmunol 82:175–181PubMedCrossRef

Del Bufalo D, Di Castro V, Biroccio A, Varmi M, Salani D, Rosano L, Trisciuoglio D, Spinella F, Bagnato A (2002) Endothelin-1 protects ovarian carcinoma cells against paclitaxel-induced apoptosis: requirement for Akt activation. Mol Pharmacol 61:524–532PubMedCrossRef

Demunter A, De Wolf-Peeters C, Degreef H, Stas M, van den Oord JJ (2001) Expression of the endothelin B receptor in pigment cell lesions of the skin. Evidence for its role as tumor progression marker in malignant melanoma. Virchows Arch 438:485–491PubMedCrossRef

Descamps G, Gomez-Bougie P, Venot C, Moreau P, Amiot M (2009) A humanized anti-IGF-1R monoclonal antibody (AVE1642) enhances bortezomib-induced apoptosis in myeloma cells lacking CD45. BJC 100:366–369PubMedPubMedCentralCrossRef

DeYoung MP, Horak P, Sofer A, Sgroi D, Ellisen LW (2008) Hypoxia regulates TSC1/2-mTOR signaling and tumor suppression through REDD1-mediated 14-3-3 shuttling. Genes Dev 22:239–251PubMedPubMedCentralCrossRef

Ehrenreich H, Anderson RW, Fox CH, Rieckmann P, Hoffman GS et al (1990) Endothelins, peptides with potent vasoactive properties are produced by human macrophages. J Exp Med 172:1741–1748PubMedCrossRef

Elshourbagy NA, Adamou JE, Gagnon AW, Wu HL, Pullen M, Nambi P (1996) Molecular characterization of a novel human endothelin receptor splice variant. J Biol Chem 271:25300–25307PubMedCrossRef

Ferone D, Hafland LJ, Colao A, Lamberts SWJ, van Hagen PM (2001) Neuroendocrine aspects of immunolymphoproliferative diseases. Ann Oncol 12:125–130CrossRef

Fingar DC, Salama S, Tsou C, Harlow E, Blenis J (2002) Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E. Gene Dev 16:1472–1487PubMedPubMedCentralCrossRef

Fisher RI, Bernstein SH, Kahl BS et al (2006) Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 24:4867–4874PubMedCrossRef

Freedman NJ, Ament AS, Oppermann M, Stoffel RH, Exum ST, Lefkowitz RJ (1997) Phosphorylation and desensitization of human endothelin A and B receptors: evidence for G protein-coupled receptor kinase specificity. J Biol Chem 272:17734–17743PubMedCrossRef

Ge NK, Rudikoff S (2000) Insulin-like growth factor 1 is a dual effector of multiple myeloma cell growth. Blood 96:2856–2861PubMed

Goldberg AL, Cascio P, Saric T, Rock KL (2002) The importance of the proteasome and subsequent proteolytic steps in the generation of antigenic peptides. Mol Immunol 39:147–164PubMedCrossRef

Gomez-Bougie P, Wuilleme-Tpumi S, Menoret E, Trichet V, Robillard N, Philippe M, Bataille R, Amiot M (2007) Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma. Cancer Res 67:5418–5424PubMedCrossRef

Grant K, Knowles J, Dawas K, Burnstock G, Taylor I, Loizidou M (2007) Mechanisms of endothelin-1 stimulated proliferation in colorectal cancer cell lines. Br J Surg 94:106–112PubMedCrossRef

He S, Dibas A, Yorio T, Prasanna G (2007) Parallel signaling pathways in endothelin-1-induced proliferation of U373MG astrocytoma cells. Exp Biol Med 232:370–384

Helleman J, Smid M, Jansen MP, van der Burg ME, Berns EM (2010) Pathway analysis of gene lists associated with platinum-based chemotherapy resistance in ovarian cancer: the big picture. Gynecol Oncol 117:170–176PubMedCrossRef

Hershko A, Ciechanover A (1998) The ubiquitin system. Annu Rev Biochem 67:425–479PubMedCrossRef

Hideshima T, Richardson PG, Anderson KC (2011) Mechanisms of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma. Mol Cancer Ther 10:2034–2042PubMedCrossRef

Ihara M, Ishikawa K, Fukuroda T, Saeki T, Funabashi K, Fukami T, Suda H, Yano M (1992) In vitro biological profile of a highly potent novel endothelin (ET) antagonist BQ-123 selective for the ETA receptor. J Cardiovasc Pharmacol 20(Suppl 12):S11–S14PubMedCrossRef

Ishikawa K, Ihara M, Noguchi K, Mase T, Mino N, Saeki T, Fukuroda T, Fukami T, Ozaki S, Nagase T et al (1994) Biochemical and pharmacological profile of a potent and selective endothelin B-receptor antagonist, BQ-788. Proc Natl Acad Sci USA 91:4892–4896PubMedPubMedCentralCrossRef

Kane RC, Bross PF, Farrell AT, Pazdur R (2003) Velcade: US FDA approval for the treatment of multiple myeloma progressing on prior therapy. Oncologist 8:508–513PubMedCrossRef

Khun DJ, Berkova Z, Jones RJ, Woessner R, Bjorklund CC, Ma W, Davis RA et al (2012) Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in pre-clinical models of multiple myeloma. Blood 120:3260–3270CrossRef

Kogner P, Ericsson A, Barbany G et al (1992) Neuropeptide Y (NPY) synthesis in lymphoblasts and increased plasma NPY in pediatric B-cell precursor leukaemia. Blood 80:1324–1329PubMed

Kojima K, Nihei Z (1995) Expression of endothelin-1 immunohistochemistry in breast cancer. Surg Onc 4:309–315CrossRef

Kondo M, Ishida N, Kobayashi M, Mitsui Y (1992) Secretion of endothelin-1 in human endothelial cell line but not in B cell line by transfection of preproendothelin-1 cDNA. Biochim Biophys Acta 1134:242–246PubMedCrossRef

Kondoh M, Miyazakli H, Watanabe H, Shibata T, Yanagisawa M, Masaki T, Murakami K (1990) Isolation of anti-endothelin receptor monoclonal antibodies for use in receptor characterization. Biochem Biophys Res Commun 172:503–510PubMedCrossRef

Kumar S, Rajkumar SV (2008) Many facets of bortezomib resistance/susceptibility. Blood 112:2177–2178PubMedCrossRef

Kumatori A, Tanaka K, Inamura N, Sone S, Ogura T, Matsumoto T, Tachikawa T, Shin S, Ichihara A (1990) Abnormally high expression of proteasomes in human leukemic cells. Proc Natl Acad Sci USA 87:7071–7075PubMedPubMedCentralCrossRef

Kurokawa K, Yamada H, Ochi J (1997) Topographical distribution of neurons containing endothelin type A receptor in the rat brain. J Comp Neurol 389:348–360PubMedCrossRef

Kusuhara M, Yamaguchi K, Nagasaki K, Hayashi C, Suzaki A, Hori S, Handa S, Nakamura Y, Abe K (1990) Production of endothelin in human cancer cell lines. Clin Cancer Res 50:3257–3261

Lahav R (2005) Endothelin receptor B is required for the expansion of melanocyte precursors and malignant melanoma. Int J Dev Biol 49:173–180PubMedCrossRef

Maffei R, Bulgarelli J, Fiorcari S, Martinelli S, Castelli I et al (2014) Endothelin-1 promotes survival and chemoresistance in Chronic Lymphocytic leukemia B Cells through ETA receptor. PLoS ONE 9:e98818PubMedPubMedCentralCrossRef

Masuda Y, Miyazaki H, Kondoh M, Watanabe H, Yanagisawa M, Masaki T, Murakami K (1989) Two different forms of endothelin receptors in rat lung. FEBS Lett 257:208–210PubMedCrossRef

Miyamoto Y, Yoshimasa T, Arai H, Takaya K, Ogawa Y, Itoh H, Nakao K (1996) Alternative RNA splicing of the human endothelin-A receptor generates multiple transcripts. Biochem J 313:795–801PubMedPubMedCentralCrossRef

Moreau P, Richardson PG, Cavo M, Orlowski RZ, San Miguel JF, Palumbo A, Harousseau J-L (2012) Proteasome inhibitors in multiple myeloma: 10 years later. Blood 120:945–959CrossRef

Nakamuta M, Ohashi M, Tabata S, Tanabe Y, Goto K, Naruse M et al (1993) High plasma concentrations of endothelin-like immunoreactivities in patients with hepatocellular carcinoma. Am J Gastroenterol 88:248–252PubMed

Nelson JB (2009) Endothelin receptors as therapeutic targets in castration-resistant prostate cancer. Eur Urol Suppl 8:20–28CrossRef

Nelson B, Chan-Tack K, Hedican P, Magnuson R, Opgenorth T, Bova G et al (1996) Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer. Cancer Res 56:663–668PubMed

Nelson J, Bagnato A, Battistini B, Nisen P (2003) The endothelin axis: emerging role in cancer. Nat Rev Cancer 3:110–116PubMedCrossRef

Nelson JB, Udan MS, Guruli G, Pflug BR (2005) Endothelin-1 inhibits apoptosis in prostate cancer. Neoplasia 7:631–637PubMedPubMedCentralCrossRef

Nilsson D, Wackenfors A, Gustafsson L, Ugander M, Ingemansson R, Edvinson L et al (2008) PKC and MAPK signaling pathways regulate vascular endothelin receptor expression. Eur J Pharmacol 580:190–200PubMedCrossRef

Oerlemans R, Franke NE, Assaraf YG et al (2008) Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein. Blood 112:2489–2499PubMedCrossRef

Osman I, Dai J, Mikhail M et al (2006) Loss of neutral endopeptidase and activation of protein kinase B (Akt) is associated with prostate cancer progression. Cancer 107:2628–2636PubMedCrossRef

Papandreou CN, Usmani B, Geng Y et al (1998) Neutral endopeptidase 24.11 loss in metastatic human prostate cancer contributes to androgen-independent progression. Nat Med 4(1):50–57PubMedCrossRef

Patrikidou A, Vlachostergios PJ, Voutsadakis IA, Hatzidaki E, Valeri R-M, Destouni C, Apostolou E, Daliani D, Papandreou CN (2011) Inverse baseline expression pattern of the NEP/neuropeptides and NFkB/proteasome pathways in androgen-dependent and androgen-independent prostate cancer cells. Cancer Cell Int 11:1–13CrossRef

Patrikidou A, Vlachostergios PJ, Voutsadakis JA, Hatzidaki E, Valeri RM, Destouni C, Apostolou E, Papandreou CN (2012) Neuropeptide inducible upregulation of proteasome activity precedes nuclear factor kappa B activation in androgen independent prostate cancer cells. Cancer Cell Int 12:31PubMedPubMedCentralCrossRef

Qiang YW, Kopantzev E, Rudikoff S (2002) Insulin-like growth factor 1 signalling in multiple myeloma: downstream elements, functional correlates and pathway cross-talk. Blood 99:4138–4146PubMedCrossRef

Rajkumar SV (2009) Multiple myeloma. Curr Probl Cancer 33:7–64PubMedCrossRef

Rajkumar SV, Richardson PG, Hideshima T, Anderson KC (2005) Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol 23:630–639PubMedCrossRef

Reddy N, Czuczman MS (2010) Enhancing activity and overcoming chemoresistance in hematologic malignancies with bortezomib: preclinical mechanistic studies. Ann Oncol 21:1756–1764PubMedCrossRef

Richardson PG, Barlogie B, Berenson J et al (2003) A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348:2609–2617PubMedCrossRef

Richardson PG, Sonneveld P, Schuster MW et al (2005) Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352:2487–2498PubMedCrossRef

Rosano L, Spinella F, Bagnato A (2013) Endothelin-1 in cancer: biological implication and therapeutic opportunities. Nat Rev Cancer 13:637–651PubMedCrossRef

Sakamoto A, Yanagisawa M, Sakurai T, Takuwa Y, Yanagisawa H, Masaki T (1991) Cloning and functional expression of human cDNA for the ETB endothelin receptor. Biochem Biophys Res Commun 178:656–663PubMedCrossRef

San Miguel JF, Schlag R, Khuageva NK et al (2008) Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 359(9):906–917PubMedCrossRef

Seece DE (2007) Management of multiple myeloma: the changing landscape. Blood Rev 21:301–314CrossRef

Shankar A, Loizidou M, Aliev G, Fredericks S, Holt D, Boulos B et al (1998) Raised endothelin 1 levels in patients with colorectal liver metastases. Br J Surg 85:502–506PubMedCrossRef

Shannon TR, Hale CC (1994) Identification of a 65 kDa endothelin receptor in bovine cardiac sarcolemmal vesicles. Eur J Pharm 267:233–238CrossRef

Shichiri M, Hirata Y, Nakajima T, Ando K, Imai T, Yanagisawa M, Masaki T, Marumo F (1991) Endothelin-1 is an autocrine/paracrine growth factor for human cancer cell lines. J Clin Invest 87:1867–1871PubMedPubMedCentralCrossRef

Shipp MA, Look AT (1993) Hematopoietic differentiation antigens that are membrane-associated enzymes: cutting is the key! Blood 84:1052–1070

Shipp MA, Tarr GE, Chen CY, Switzer SN, Hersh LB, Steins H, Sundays ME, Reinherz EL (1991) CD10/neutral endopeptidase 24.11 hydrolyzes bombesin-like peptides and regulates the growth of small cell carcinomas of the lung. Proc Natl Acad Sci USA 88:10662–10666PubMedPubMedCentralCrossRef

Shuqing Lu, Wang Jianmin (2013) The resistance mechanisms of proteasome inhibitor bortezomib. Biomark Res 1:13CrossRef

Simonson M, Dunn M (1990) Cellular signaling by peptides of the endothelin gene family. FASEB J 4:2989–3000PubMed

Smollich M, Wulfing P (2007) The endothelin axis: a novel target for pharmacotherapy of female malignancies. Curr Vasc Pharmacol 5:239–248PubMedCrossRef

Spinella F, Rosano L, Di Castro V, Nicotra MR, Natali PG, Bagnato A (2003) Endothelin-1 decreases gap junctional intercellular communication by inducing phosphorylation of connexin 43 in human ovarian carcinoma cells. J Biol Chem 278:41294–41301PubMedCrossRef

Spinella F, Rosano L, Di Castro V, Nicotra MR, Natali PG, Bagnato A (2004) Inhibition of cyclooxygenase-1 and -2 expression by targeting the endothelin a receptor in human ovarian carcinoma cells. Clin Cancer Res 10:4670–4679PubMedCrossRef

Takasura T, Sakurai T, Goto K, Furuichi Y, Watanabe T (1994) Human endothelin recptor ETB. J Biol Chem 269:7509–7513

Tamkus T, Leece C, Gallo K, Madhukar BV, Dimitrov N (2011) Endothelin-1/endothelin A receptor signaling in breast cancer, poster session 2. Cancer Res 71(24 Suppl): Abstract nr P2-03-06

Testa JR, Bellacosa A (2001) AKT plays a central role in tumorigenesis. Proc Natl Acad Sci USA 98:10983–10985PubMedPubMedCentralCrossRef

Tsapakidis K, Vlachostergios PJ, Voutsadakis JA, Befani CD, Patrikidou A, Hatzidaki E, Daliani DD, Moutzouris G, Liakos P, Papandreou CN (2012) Bortezomib reverses the proliferative and antiapoptotic effect of neuropeptides on prostate cancer cells. Int J Urol 19:565–574PubMedCrossRef

Tsutsumi M, Liang G, Jones PA (1999) Novel endothelin B receptor transcripts with the potential of generating a new receptor. Gene 228:43–49PubMedCrossRef

Voortman J, Checinska A, Giaccone G (2007) The proteasomal and apoptotic phenotype determine bortezomib sensitivity of non-small cell lung cancer cells. Mol Cancer 6:73PubMedPubMedCentralCrossRef

Warzocha K, Kraj M, Poglod R, Kwasniak B (2008) Bortezomib in multiple myeloma: treatment and retreatment. A single center experience. Acta Pol Pharm 65:753–756PubMed

Wolf J, Richardson PG, Schuster M, BlancA Le, Walters IB, Battleman DS (2008) Utility of bortezomib retreatment in relapsed or refractory multiple myeloma patients: a multicenter case series. Clin Adv Hematol Oncol 6:755–760PubMed

Wu-Wong JR, Chiou WJ, Wang J (2000) Extracellular signal-regulated kinases are involved in the antiapoptotic effect of endothelin-1. J Pharmacol Exp Ther 293:514–521PubMed

Xu GW, Ali M, Wood TE, Wong D, Maclean N, Wang X, Gronda M, Skrtic M, Li X, Hurren R, Mao X, Veukatesan M, Beheshti Zavareh R, Ketela T, Reed JC, Rose D, Moffat J, Batey RA, Dhe-Paganon S, Schimmer AD (2010) The ubiquitin-activating enzyme E1 as a therapeutic target for the treatment of leukemia and multiple myeloma. Blood 115:2251–2259PubMedPubMedCentralCrossRef

Yamaguchi E, Yamanoi A, Ono T, Nagasue N (2007) Experimental investigation of the role of endothelin-1 in idiopathic portal hypertension. J Gastroenterol Hepatol 22:1134–1140PubMedCrossRef

Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S, Epstein J, Yaccob Sh et al (2006) The molecular classification of multiple myeloma. Blood 108:2020–2028PubMedPubMedCentralCrossRef

Zhang X, Krishnamoorthy RR, Prasanna G, Narayan S, Clark A, Yorio T (2003a) Dexamethasone regulates endothelin-1 and endothelin receptors in human non-pigmented ciliary epithelial (HNPE) cells. Exp Eye Res 76:261–272PubMedCrossRef

Zhang YM, Wang K-Q, Zhou G-M, Zuo J, Ge J-B (2003b) Endothelin-1 promoted proliferation of vascular smooth muscle cell through pathway of extracellular signal-regulated kinase and cyclin D1. Acta Pharmacol Sin 24:563–568PubMed

Zhou L, Hou J, Fu W, Wang D, Yuan Z, Jiang H (2008) Arsenic trioxide and 2-methoxyestradiol reduce β-catenin accumulation after proteasome inhibition and enhance the sensitivity of myeloma cells to bortezomib. Leuk Res 32:1674–1683PubMedCrossRef

Zhou Y, Barlogie B, Shaughnessy JD (2009) The molecular characterization and clinical management of multiple myeloma in the post-genome era. Leukemia 23(11):1941–1956PubMedPubMedCentralCrossRef

Titel: Endothelin-1 (ET-1) induces resistance to bortezomib in human multiple myeloma cells via a pathway involving the ETB receptor and upregulation of proteasomal activity
verfasst von: Maria Vaiou
Evanthia Pangou
Panagiotis Liakos
Nikos Sakellaridis
George Vassilopoulos
Konstantinos Dimas
Christos Papandreou
Publikationsdatum: 16.08.2016
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 10/2016
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-016-2216-2

Neu im Fachgebiet Onkologie

22.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Endothelin-1 (ET-1) induces resistance to bortezomib in human multiple myeloma cells via a pathway involving the ETB receptor and upregulation of proteasomal activity

Abstract

Purpose

Methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

AML: Komplettremission kein Muss für erfolgreiche Stammzelltransplantation

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2016

Bone morphogenetic protein signaling in musculoskeletal cancer

Robot-assisted surgery versus conventional laparoscopic surgery for endometrial cancer: a systematic review and meta-analysis

Metformin in pancreatic cancer treatment: from clinical trials through basic research to biomarker quantification

Effects of Raf kinase inhibitor protein expression on pancreatic cancer cell growth and motility: an in vivo and in vitro study

Classical risk factors, but not HPV status, predict survival after chemoradiotherapy in advanced head and neck cancer patients

MassARRAY, pyrosequencing, and PNA clamping for EGFR mutation detection in lung cancer tissue and cytological samples: a multicenter study

Neu im Fachgebiet Onkologie

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

AML: Komplettremission kein Muss für erfolgreiche Stammzelltransplantation

Update Onkologie